

Supplemental Table 1

Fluorochrome conjugated antibodies used for flow cytometric analysis.

Stain	Colour	Clone	Isotype	Company
Viability dye	Aqua/BV510		N/A	Thermo Fisher Scientific
CD3	PerCP	UCHT1	N/A	Biolegend
CD4	Pac Blue	RPA-T4	N/A	Biolegend
CD8	APC-Cy7	SK1	N/A	Biolegend
CD45RA	PE Cy7	HI100	N/A	Biolegend
CD27	AF700	M-T271	N/A	Biolegend
CD14	BUV805	M5E2	N/A	BD Biosciences
CD16	BV786	3G8	N/A	Biolegend
CD31	BUV 395	WM59	IgG1, k	BD Biosciences
CD95	APC	DX2	IgG1, k	BD Biosciences
CD28	BV711	CD28.2	IgG1, k	Biolegend
CD38	PE	HIT2	IgG1, k	BD Biosciences
CD127	BV605	A019D5	IgG1, k	Biolegend
HLA-DR	PE-CF594	G46-6	IgG1, k	BD Biosciences

Supplemental Table 2

Characteristics of secondary cohort participants

Sample size	n=15
DAA Regimen; * No. (%)	
Sofosbuvir/velpatasvir	4 (26.6%)
Ledipasvir/sofosbuvir	10 (66.7%)
Elbasvir/grazoprevir	1 (6.7%)
HCV Genotype; * No. (%)	
1a	6 (40%)
1b	4 (27%)
2	2 (13%)
3	2 (13%)
4	1 (7%)
Plasma HCV RNA level (IU/L)	1,360,000 (811,000-4,130,000)
Serum Albumin level (g/dL)	3.9 (3.7-4)
Serum ALT level (IU/L)	52 (27-87)
Serum AST level (IU/L)	42 (31-77)
Platelets (K/ul)	186 (162-232)
APRI, AST/PLT index; * No. (%)	
<0.4	11 (73%)
0.4-1.5	4 (27%)
>1.5	0 (0%)
FIB-4 score	2 (01.2-2.7)
CD4 cells/mm³	622 (529-1022)
Age, years	58 (48-61)
Gender; * No. (%)	
Male	12 (80%)
Female	2 (13%)
Transgender	1 (7%)
Race/ethnicity; * No. (%)	
Black	7 (47%)
White	5 (33%)
Hispanic	3 (20%)
Hispanic	16 (20%)

Data are Median (25th , 75th percentiles), unless otherwise indicated *